Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2009

View Archived Issues

New venlafaxine prodrugs for depression imparted by Solvay

CrystaX scientists claim Hsp90 inhibitors and their use in cancer therapy

Sanofi-aventis presents novel PKB inhibitors for cancer

Novel PARP inhibitors under development at Abbott for the treatment of cancer

Indeglitazar, a pan-agonist of PPARs, entering phase II trial for type 2 diabetes mellitus

Gel and intravaginal ring forms of IQP-0528 are being developed as topical HIV microbicides

EMEA accepts for review Genmab's Arzerra NDA

MannKind updates NDA submission status for Afresa

RegeneRx provides update on phase II RGN-137 trial in venous stasis

Theravance receives FDA complete response letter for telavancin NDA

Cephalon intends to make a cash takeover offer to Arana

DSMB recommends continuation of phase III clinical trial of GTx's toremifene

MedImmune licenses biologics drug for treating asthma from La Jolla

Serenity completes phase II clinical trial of CPEX Pharmaceuticals' urology drug

MabThera approved in the E.U. for patients with chronic lymphocytic leukemia

AstraZeneca receives FDA complete response letter for Seroquel XR sNDA

Somaxon receives FDA complete response letter for Silenor

Phase II study shows potential benefit of erlotinib before cystectomy for bladder cancer

AZD-0530 inhibits cell growth and migration in human bladder cancer in vitro

Astellas commences tender offer to acquire outstanding shares of CV Therapeutics

Nitec completes recruitment in phase III Lodotra trial in rheumatoid arthritis

FDA approves Symbicort for chronic obstructive pulmonary disease

The Medicines Company acquires Targanta Therapeutics

Pharmaxis submits NDA to FDA for Aridol

Salix receives FDA complete response letter for Metozolv ODT

Abbott claims new Aurora kinase inhibitors as oncolytic agents